Kevan L. Hartshorn, MD
Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MD, Albert Einstein College of Medicine
MA, Williams College



Expertise includes: Innate immunity to respiratory infection; Neutrophil Biology; Influenza Virus; Gastrointestinal cancer.

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Division of Graduate Medical Sciences


Active Staff Privileges
Boston Medical Center
Medicine
Hematology & Medical Oncology


2010-2010 Boston Magazine: Selected as one of Boston's Top Doctors for 2010


A Randomized, Double-blind, Phase II Study of RAD001 10 mg/d plus Best Supportive Care versus Placebeo plus Best Supportive Care in the Treatment of Patients with Advanced Pancreatic Neuroendocri
04/04/2008 - 04/30/2011 (PI)
Novartis Pharmaceuticals Corporation


A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care vs placebo, plus best best supportive care in patients with advanced gastric cance
03/16/2010 - 02/28/2011 (PI)
Novartis Pharmaceuticals Corporation


A Phase II, Multi-center, Open-label Trial to Evaluate the Efficacy and Safety of DAVANAT in Combination with 5-Fluorouracil when Administered as First Line Chemotherapy in Patients Advanced Bili
07/05/2007 - 07/04/2010 (PI)
Pro-Pharmaceuticals, Inc.


A Randomized, Open-Label Trial Comparing Two Avastin (bevacizumab)- Based Treatment Regimens for the First-Line Treatment of Metastatic Colorectal Cancer
05/17/2006 - 12/31/2009 (PI)
Genentech, Inc.

Enhancing Collectin Mediated Host Defense
04/01/1998 - 03/31/2003 (PI)
NIH/National Heart, Lung, and Blood Institute
5 R01 HL58910 04

An Open Label, Randomized, Controlled, Phase III, Multicenter, Clinical Trial of PN401 with HighDose 5-Fluoraouracil (5FU) vs. Gemcitabine for Treatment of Patients with Advanced Pancreatic Cancer
12/01/2001 - 11/30/2002 (PI)
Pro-Neuron


Enhancing Collectin Mediated Defense Against Influenza
07/01/2015 - 06/30/2019 (PI)
NIH-NHLBI

The JANUS 1 Study
08/26/2015 - 08/31/2018 (PI)
Incyte Corporation

A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib of Placebo in Comb…
01/15/2015 - 01/31/2018 (PI)
Incyte Corporation

Enhancing Collectin Medicated Defense Against Influenza
08/11/2011 - 06/30/2015 (PI)
NIH-NHLBI

Development of Novel Immunotherapy for Influenza Virus Infection
09/01/2007 - 08/31/2013 (PI)
Mass General Hosp NIH-NIAID

Collectins and Innate Defense against Inhaled Pathogens
09/01/2009 - 08/31/2012 (PI)
Trustees of Boston University NIH-NIAID

Collectins and Innate Defense against Inhaled Pathogens
09/30/2009 - 08/31/2011 (PI)
Trustees of Boston University NIH-NIAID

Collectin-Mediated Defense Against Influenza
04/01/2006 - 08/10/2011 (PI)
NIH-NIDDK

Innate Immunity in the Clearance of Influenza A Virus Ifected Apoptotic Cells
09/25/2007 - 08/31/2010 (PI)
Mass General Hosp NIH-NIAID

Novel Genetically Targeted Antiviral Agents
07/01/2005 - 06/30/2007 (PI)
Harvard Medical School NIH-NIAID

Showing 10 of 11 results. Show All Results


Yr Title Project-Sub Proj Pubs
2016 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-15 31
2014 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-13 31
2013 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-12 31
2012 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-11 31
2011 Enhancing Collectin Mediated Defense Against Influenza 2R01HL069031-10 31
2010 Collectin-Mediated Defense Against Influenza 5R01HL069031-09 31
2009 Collectin-Mediated Defense Against Influenza 5R01HL069031-08 31
2008 Collectin-Mediated Defense Against Influenza 5R01HL069031-07 31
2007 Collectin-Mediated Defense Against Influenza 5R01HL069031-06 31
2006 Collectin-Mediated Defense Against Influenza 2R01HL069031-05A1 31
Showing 10 of 26 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Nikolaidis NM, Noel JG, Pitstick LB, Gardner JC, Uehara Y, Wu H, Saito A, Lewnard KE, Liu H, White MR, Hartshorn KL, McCormack FX. Mitogenic stimulation accelerates influenza-induced mortality by increasing susceptibility of alveolar type II cells to infection. Proc Natl Acad Sci U S A. 2017 Aug 08; 114(32):E6613-E6622. PMID: 28739896.
  2. Tapan U, Lee SY, Weinberg J, Kolachalama VB, Francis J, Charlot M, Hartshorn K, Chitalia V. Racial differences in colorectal cancer survival at a safety net hospital. Cancer Epidemiol. 2017 08; 49:30-37.View Related Profiles. PMID: 28538169.
  3. De Luna X, Hartshorn KL. Influenza Casts a Lung Shadow. Am J Pathol. 2017 Apr; 187(4):697-699. PMID: 28222276; DOI: 10.1016/j.ajpath.2017.01.007;.
  4. Elias R, Karantanos T, Sira E, Hartshorn KL. Immunotherapy comes of age: Immune aging & checkpoint inhibitors. J Geriatr Oncol. 2017 May; 8(3):229-235. PMID: 28223073; DOI: 10.1016/j.jgo.2017.02.001;.
  5. Chua MM, Ortega CE, Sheikh A, Lee M, Abdul-Rassoul H, Hartshorn KL, Dominguez I. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. Pharmaceuticals (Basel). 2017 Jan 28; 10(1).View Related Profiles. PMID: 28134850; DOI: 10.3390/ph10010018;.
  6. Phull P, Quillen K, Hartshorn KL. Acute Oxaliplatin-induced Hemolytic Anemia, Thrombocytopenia, and Renal Failure: Case Report and a Literature Review. Clin Colorectal Cancer. 2016 Nov 23.View Related Profiles. PMID: 27989485; DOI: 10.1016/j.clcc.2016.11.005;.
  7. White MR, Tripathi S, Verma A, Kingma P, Takahashi K, Jensenius J, Thiel S, Wang G, Crouch EC, Hartshorn KL. Collectins, H-ficolin and LL-37 reduce influence viral replication in human monocytes and modulate virus-induced cytokine production. Innate Immun. 2017 Jan; 23(1):77-88.View Related Profiles. PMID: 27856789; DOI: 10.1177/1753425916678470;.
  8. Shashar M, Siwak J, Tapan U, Lee SY, Meyer RD, Parrack P, Tan J, Khatami F, Francis J, Zhao Q, Hartshorn K, Kolachalama VB, Rahimi N, Chitalia V. c-Cbl mediates the degradation of tumorigenic nuclear ß-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors. Oncotarget. 2016 11 01; 7(44):71136-71150.View Related Profiles. PMID: 27661103; DOI: 10.18632/oncotarget.12107;.
  9. Lee SY, Sissoko M, Hartshorn KL. Update on the Management of Pancreatic Cancer in Older Adults. Curr Oncol Rep. 2016 Oct; 18(10):60. PMID: 27492426; DOI: 10.1007/s11912-016-0547-4;.
  10. Chelimeda S, Bejarano T, Lowe R, Soliman M, Zhao Q, Hartshorn KL. Long-Term Survival after Resection of Lung Metastases from Hepatocellular Cancer: Report of a Case and Review of the Literature. Case Rep Oncol. 2016 Sep-Dec; 9(3):559-564.View Related Profiles. PMID: 27790121.
Showing 10 of 149 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 149 publications over 32 distinct years, with a maximum of 11 publications in 2012

YearPublications
19851
19862
19876
19882
19892
19904
19923
19933
19945
19951
19963
19971
19983
19993
20007
20016
20026
20033
20043
20055
20065
20075
20084
20099
20109
20117
201211
20137
20146
20154
20168
20175
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Gastrointestinal cancer
Innate Immunity
Neutrophils
Contact for Mentoring:


650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map


Hartshorn's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department